MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer

Autor: Jeong Eon Lee, Haein Kim, Jinil Han, Joon Seok Choi, Sarah Park, Young Kee Shin, Yoon-La Choi, Jong Sun Choi, Byung-Ho Nam, Seok Jin Nam, Jun Young Choi, Se Kyung Lee, Young Deug Kim, Mi Jeong Kwon
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Multivariate analysis
Receptor
ErbB-2
CD2 Antigens
Breast Neoplasms
Disease-Free Survival
Risk of distant metastasis
03 medical and health sciences
0302 clinical medicine
Immune system
Breast cancer
Preclinical Study
Matrix Metalloproteinase 11
Internal medicine
medicine
Biomarkers
Tumor
Humans
skin and connective tissue diseases
HER2-positive (HR−/HER2+) breast cancer
Aged
Cell Proliferation
Aged
80 and over
Univariate analysis
Framingham Risk Score
business.industry
Hormone receptor-negative
Cancer
Middle Aged
medicine.disease
Prognosis
Immunity
Innate
Gene Expression Regulation
Neoplastic
030104 developmental biology
Hormone receptor
030220 oncology & carcinogenesis
Lymphatic Metastasis
Proliferation-related genes (p-genes)
Female
business
Prognostic model
Immune response-related genes (i-genes)
Hormone
Zdroj: Breast Cancer Research and Treatment
ISSN: 1573-7217
Popis: Purpose More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. Methods We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype. Results The prognostic significance of clinical and gene variables varied according to the molecular subtype. Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR−/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2− subtype, whereas i-genes correlated with a favorable outcome in patients with HR−/HER2+ breast cancer. In HR−/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS). A new prognostic model for HR−/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. Multivariate analyses revealed that our risk score is an independent prognostic factor for DMFS. Moreover, C-index showed that our risk score has a superior prognostic performance to traditional clinicopathological factors. Conclusions Our new prognostic model for HR−/HER2+ breast cancer provides more accurate information on the risk of distant metastasis than traditional clinical prognostic factors and may be used to identify patients with a good prognosis in this aggressive subtype of breast cancer. Electronic supplementary material The online version of this article (doi:10.1007/s10549-017-4234-4) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: